Ticagrelor Tablets

DRUG3 trials

Sponsors

AstraZeneca, Shanghai Haiyan Pharmaceutical Technology Co., Ltd., Advenchen Laboratories Nanjing Ltd.

Conditions

Coronary Artery DiseaseHealthy VolunteerInsomnia

Phase 1

A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects

Active, not recruitingNCT06671470

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Insomnia

Start: 2024-08-22End: 2024-12-31Updated: 2024-11-04

Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers

Not yet recruitingNCT07438886

Advenchen Laboratories Nanjing Ltd.Healthy Volunteer

Start: 2026-03-02End: 2027-03-31Target: 16Updated: 2026-02-27

Phase 2

A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

CompletedNCT00528411

AstraZenecaCoronary Artery Disease

Start: 2007-10-31End: 2009-03-31Updated: 2012-01-13

Related Papers

Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.

2010-07-01132 citations